Nortech Systems Incorporated — Q1 2024 Form 10-Q Summary
Business context and reporting period
Nortech Systems is a global electronics manufacturing services company serving the medical, aerospace and defense, and industrial markets. The filing covers the three months ended March 31, 2024, compared with the three months ended March 31, 2023. The company operates facilities in Minnesota, Mexico, and China.
Key financial metrics
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Net sales | $34.215 million | $34.888 million | Down 1.9% |
| Gross profit | $5.448 million | $5.484 million | Down 0.7% |
| Gross margin | 15.9% | 15.7% | Up 20 basis points |
| Operating income | $1.155 million | $1.053 million | Up 9.7% |
| Operating margin | 3.4% | 3.0% | Improved |
| Net income | $765 thousand | $681 thousand | Up 12.3% |
| Diluted EPS | $0.26 | $0.23 | Up $0.03 |
| Net cash from operating activities | $2.828 million | $1.718 million | Up $1.110 million |
| Capital expenditures | $744 thousand | $496 thousand | Up $248 thousand |
Net margin was approximately 2.2% in Q1 2024 versus approximately 2.0% in Q1 2023. Interest expense increased to $167 thousand from $110 thousand, reflecting higher borrowing rates. The effective tax rate declined to 22.6% from 27.8%, primarily due to estimated research and development tax credits and the prior-year valuation allowance.
At March 31, 2024, cash was $4.028 million, accounts receivable were $16.051 million, inventories were $22.951 million, and contract assets were $14.194 million. Total current assets were $59.116 million compared with current liabilities of $25.721 million. The company had $6.220 million of line-of-credit borrowings, $8.780 million of unused availability, and total lease liabilities of $8.676 million.
Material changes versus the prior comparable period
- Medical revenue decreased 5.1% to $20.282 million, and industrial revenue decreased 14.8% to $8.073 million, primarily as customers worked through inventory.
- Aerospace and defense revenue increased 44.9% to $5.860 million due to stronger demand and improved access to component parts.
- Gross margin improved due primarily to favorable product mix, despite a $178 thousand catch-up accrual for Mexican statutory benefits.
- Selling and general and administrative expenses declined, while research and development expense increased to $318 thousand from $276 thousand.
- Operating cash flow improved substantially, principally from collections of accounts receivable and contract assets. Inventory used $1.400 million of cash compared with providing $1.075 million in the prior-year quarter.
- The company replaced its prior asset-backed credit facility on February 29, 2024, with a $15 million senior secured revolving line of credit expiring February 28, 2027. The new facility bears interest based on a base rate or SOFR plus a margin.
- The company reported a prospective out-of-period adjustment that reduced Q1 2024 net income by approximately $178 thousand for previously understated accrued liabilities as of December 31, 2023. Management concluded the error was not material.
Backlog, outlook, risks, and unusual items
Management stated that existing financing arrangements, anticipated operating cash flows, and cash on hand should be sufficient for working capital, capital expenditures, and debt repayments over the next twelve months.
The 90-day shipment backlog was $35.213 million at March 31, 2024, essentially level with December 31, 2023 and up 4.1% year over year. Total backlog was $86.001 million, down 6.2% from the beginning of the quarter and down 13.0% from March 31, 2023. Management noted reduced revenue visibility as customers balance inventories and defer some orders.
The company met the revolving credit facility’s maximum 2.5 times leverage and minimum 1.25 times fixed-charge coverage covenants at March 31, 2024. Borrowings are exposed to changes in SOFR, and the facility is secured by substantially all company assets.
- Key risks include customer concentration, demand volatility, supply-chain disruption, labor availability, component and commodity costs, competition, foreign currency movements, regulatory and FDA compliance, cybersecurity or information-system disruption, and loss of a major customer.
- Two customers represented 35% of Q1 2024 net sales, and two customers represented approximately 37% of gross accounts receivable at March 31, 2024.
- Approximately 74% of net sales were recognized over time under contract manufacturing agreements.
- Legal proceedings are described as ordinary-course matters; no material litigation is identified in the provided filing text.
- Management reported effective disclosure controls and no material change in internal control over financial reporting.
Important facts for investors to verify
- Whether medical and industrial demand recovers after customer inventory reductions and whether aerospace and defense growth continues.
- The timing and collectability of the $14.194 million contract-asset balance and the concentration of receivables among major customers.
- Compliance with the new revolver’s leverage, fixed-charge coverage, capital expenditure, and other covenants as interest rates fluctuate.
- The effect of the $178 thousand out-of-period adjustment and the related Mexican statutory-benefit accrual on full-year results.
- Backlog conversion, particularly given the 13.0% year-over-year decline in total backlog and management’s reduced revenue visibility.
- Exposure to customer concentration, supply-chain constraints, foreign operations, foreign currency losses, and regulatory or cybersecurity events.